• 1
    Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 2009; 50: 19551966.
  • 2
    Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile Acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147191.
  • 3
    Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007; 67: 13831392.
  • 4
    Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99: 257273.
  • 5
    Donovan JM, Von BK, Setchell KD, Isaacsohn J, Pappu AS, Illingworth DR, et al. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci 2005; 50: 12321238.
  • 6
    Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008; 168: 19751983.
  • 7
    Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008; 31: 14791484.
  • 8
    Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007; 29: 7483.
  • 9
    Beil U, Crouse JR, Einarsson K, Grundy SM. Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism 1982; 31: 438444.
  • 10
    Crouse JR III. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 1987; 83: 243248.
  • 11
    Angelin B, Einarsson K, Hellstrom K, Leijd B. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. J Lipid Res 1978; 19: 10171024.
  • 12
    Carulli N, Ponz de LM, Podda M, Zuin M, Strata A, Frigerio G, et al. Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial. J Clin Pharmacol 1981; 21: 436442.
  • 13
    Kuipers F, Stroeve JH, Caron S, Staels B. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr Opin Lipidol 2007; 18: 289297.
  • 14
    Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006; 281: 1103911049.
  • 15
    Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006; 103: 10061011.
  • 16
    Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102: 731744.
  • 17
    Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 14081418.
  • 18
    Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159: 18931900.
  • 19
    Kok T, Hulzebos CV, Wolters H, Havinga R, Agellon LB, Stellaard F, et al. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J Biol Chem 2003; 278: 4193041937.
  • 20
    Plosch T, van der Veen JN, Havinga R, Huijkman NC, Bloks VW, Kuipers F. Abcg5/Abcg8-independent pathways contribute to hepatobiliary cholesterol secretion in mice. Am J Physiol Gastrointest Liver Physiol 2006; 291: G414G423.
  • 21
    Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911917.
  • 22
    Murphy GM, Billing BH, Baron DN. A fluorimetric and enzymatic method for the estimation of serum total bile acids. J Clin Pathol 1970; 23: 594598.
  • 23
    Hulzebos CV, Renfurm L, Bandsma RH, Verkade HJ, Boer T, Boverhof R, et al. Measurement of parameters of cholic acid kinetics in plasma using a microscale stable isotope dilution technique: application to rodents and humans. J Lipid Res 2001; 42: 19231929.
  • 24
    Tancevski I, Wehinger A, Demetz E, Eller P, Duwensee K, Huber J, et al. Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5′-triphosphate-binding cassette transporter 1 expression. Endocrinology 2008; 149: 37083712.
  • 25
    Jung HR, Turner SM, Neese RA, Young SG, Hellerstein MK. Metabolic adaptations to dietary fat malabsorption in chylomicron-deficient mice. Biochem J 1999; 343: 473478.
  • 26
    Neese RA, Faix D, Kletke C, Wu K, Wang AC, Shackleton CH, et al. Measurement of endogenous synthesis of plasma cholesterol in rats and humans using MIDA. Am J Physiol 1993; 264: E136E147.
  • 27
    Wiegman CH, Bandsma RH, Ouwens M, van der Sluijs FH, Havinga R, Boer T, et al. Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes 2003; 52: 10811089.
  • 28
    Oosterveer MH, van Dijk TH, Tietge UJ, Boer T, Havinga R, Stellaard F, et al. High fat feeding induces hepatic fatty acid elongation in mice. PLoS One 2009; 4: e6066.
  • 29
    Plosch T, Kok T, Bloks VW, Smit MJ, Havinga R, Chimini G, et al. Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J Biol Chem 2002; 277: 3387033877.
  • 30
    Biddinger SB, Haas JT, Yu BB, Bezy O, Jing E, Zhang W, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008; 14: 778782.
  • 31
    van Waarde WM, Verkade HJ, Wolters H, Havinga R, Baller J, Bloks V, et al. Differential effects of streptozotocin-induced diabetes on expression of hepatic ABC-transporters in rats. Gastroenterology 2002; 122: 18421852.
  • 32
    Li T, Ma H, Chiang JY. Transforming growth factor beta 1, tumor necrosis factor a, and insulin signaling crosstalk in regulation of the rat cholesterol 7alpha -hydroxylase gene expression. J Lipid Res 2008; 49: 19811989.
  • 33
    Hay DW, Carey MC. Pathophysiology and pathogenesis of cholesterol gallstone formation. Semin Liver Dis 1990; 10: 159170.
  • 34
    Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. HEPATOLOGY 2000; 31: 299303.
  • 35
    Xu G, Pan LX, Li H, Forman BM, Erickson SK, Shefer S, et al. Regulation of the farnesoid X receptor (FXR) by bile acid flux in rabbits. J Biol Chem 2002; 277: 5049150496.
  • 36
    Kobayashi M, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, Noso S, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007; 56: 239247.
  • 37
    Sakamoto S, Takeshita S, Sassa S, Suzuki S, Ishikawa Y, Kudo H. Effects of colestimide and/or Bofu-tsusho-san on plasma and liver lipids in mice fed a high-fat diet. In Vivo 2005; 19: 10291033.
  • 38
    Bilz S, Samuel V, Morino K, Savage D, Choi CS, Shulman GI. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am J Physiol Endocrinol Metab 2006; 290: E716E722.
  • 39
    Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH, et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 2005; 280: 2997129979.
  • 40
    Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 2004; 18: 157169.
  • 41
    Matsukuma KE, Bennett MK, Huang J, Wang L, Gil G, Osborne TF. Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase. J Lipid Res 2006; 47: 27542761.
  • 42
    Grefhorst A, van Dijk TH, Hammer A, van der Sluijs FH, Havinga R, Havekes LM, et al. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab 2005; 289: E829E838.
  • 43
    Jungermann K, Kietzmann T. Zonation of parenchymal and nonparenchymal metabolism in liver. Annu Rev Nutr 1996; 16: 179203.
  • 44
    Wang J, Olin M, Rozell B, Bjorkhem I, Einarsson C, Eggertsen G, et al. Differential hepatocellular zonation pattern of cholesterol 7alpha-hydroxylase (Cyp7a1) and sterol 12alpha-hydroxylase (Cyp8b1) in the mouse. Histochem Cell Biol 2007; 127: 253261.
  • 45
    Twisk J, Hoekman MF, Mager WH, Moorman AF, de Boer PA, Scheja L, et al. Heterogeneous expression of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase genes in the rat liver lobulus. J Clin Invest 1995; 95: 12351243.
  • 46
    Groothuis GM, Meijer DK. Hepatocyte heterogeneity in bile formation and hepatobiliary transport of drugs. Enzyme 1992; 46: 94138.